Literature DB >> 11400144

Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution.

H Buerger1, E C Mommers, R Littmann, R Simon, R Diallo, C Poremba, B Dockhorn-Dworniczak, P J van Diest, W Boecker.   

Abstract

Ductal invasive grade (G) 2 and G3 carcinomas represent the majority of invasive breast cancers. Previous morphological and cytogenetic studies have provided evidence that ductal invasive G2 carcinoma may originate from at least two different genetic pathways. The aim of this study was to evaluate further the heterogeneity of G2 breast cancer in comparison with G3 cancers by cytogenetic and quantitative analysis. To this end, 35 cases of ductal invasive G2 and 42 cases of ductal invasive G3 carcinomas were investigated by means of comparative genomic hybridization (CGH) and these findings were correlated with DNA ploidy status, mitotic activity index (MAI), mean nuclear area (MNA), volume per lumen (VPL), and clinico-pathological parameters. The findings of this study demonstrate that ductal invasive G2 carcinomas, in contrast to ductal invasive G3 carcinomas, have to be interpreted as the morphological end stage resulting from two different cytogenetic and morphological pathways; the loss of 16q material is the cytogenetic key event in the evolution of a subgroup of this entity. By correlating genetic alterations with DNA ploidy status, an extended morphology-based cytogenetic progression model is presented, with early and late genetic alterations in the pathogenesis of breast cancer. The correlation with MAI gives rise to the hypothesis that these different genetic pathways significantly differ in their proliferation rate. Further studies will be required to elucidate which genes contribute to an altered proliferation rate in these subgroups and to the associated prognosis. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400144     DOI: 10.1002/path.875

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  36 in total

Review 1.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

Review 2.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

3.  [Prognostic factors in ductal carcinoma in situ].

Authors:  A Lebeau
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

4.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

5.  Cytogenetic differences in breast cancer samples between German and Japanese patients.

Authors:  J Packeisen; K Nakachi; W Boecker; B Brandt; H Buerger
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

6.  The diagnostic challenge of low-grade ductal carcinoma in situ.

Authors:  Tracy Onega; Donald L Weaver; Paul D Frederick; Kimberly H Allison; Anna N A Tosteson; Patricia A Carney; Berta M Geller; Gary M Longton; Heidi D Nelson; Natalia V Oster; Margaret S Pepe; Joann G Elmore
Journal:  Eur J Cancer       Date:  2017-05-20       Impact factor: 9.162

7.  Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.

Authors:  Kerstin Heselmeyer-Haddad; Lissa Y Berroa Garcia; Amanda Bradley; Clarymar Ortiz-Melendez; Woei-Jyh Lee; Rebecca Christensen; Sheila A Prindiville; Kathleen A Calzone; Peter W Soballe; Yue Hu; Salim A Chowdhury; Russell Schwartz; Alejandro A Schäffer; Thomas Ried
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

8.  Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.

Authors:  H Wong; S Lau; T Yau; P Cheung; R J Epstein
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  Genomic heterogeneity of breast tumor pathogenesis.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Clin Med Oncol       Date:  2009-07-29

10.  Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study.

Authors:  Ikechukwu Uzoaru; Bradley R Morgan; Zheng G Liu; Frank J Bellafiore; Farah S Gaudier; Jeanne V Lo; Kourosh Pakzad
Journal:  Virchows Arch       Date:  2012-09-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.